Status:
RECRUITING
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Lead Sponsor:
Federico Martinón Torres
Conditions:
RSV Infection
Eligibility:
All Genders
1-24 years
Brief Summary
A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data ...
Detailed Description
The purpose of this study is to evaluate the impact of nirsevimab in preventing RSV in healthy infants and high-risk children less than 24 months of age at the start of RSV season in Galicia. The tar...
Eligibility Criteria
Inclusion
- Subjects born in Galicia from April 1st, 2023 and March 1st, 2026
Exclusion
- No specific criteria has been reported
Key Trial Info
Start Date :
September 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2026
Estimated Enrollment :
42000 Patients enrolled
Trial Details
Trial ID
NCT06180993
Start Date
September 25 2023
End Date
October 31 2026
Last Update
December 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain, 15707